Search

Your search keyword '"Midthun, David E."' showing total 257 results
Start Over Author "Midthun, David E." Language english
257 results on '"Midthun, David E."'

3. Lung Cancer Screening Guidelines Implementation in Primary Care: A Call to Action

Author

Doubeni, Chyke A., Wilkinson, John M., Korsen, Neil, and Midthun, David E.

Subjects
Cancer -- Diagnosis, Practice guidelines (Medicine) -- Methods, Lung cancer -- Diagnosis -- Prevention, Primary health care -- Methods, Health, Science and technology
Abstract

A man aged 60 years presented to his primary care physician because of a 5-kg unintentional weight loss over 3 months, hemoptysis, and exertional shortness of breath, but no fever. [...]

Published
2020
Full Text
View/download PDF

5. Management of Multifocal Lung Cancer: Results of a Survey

Author

Leventakos, Konstantinos, Peikert, Tobias, Midthun, David E., Molina, Julian R., Blackmon, Shanda, Nichols, Francis C., Garces, Yolanda I., Hallemeier, Christopher L., Murphy, Stephen J., Vasmatzis, George, Kratz, Sarah L., Holland, William P., Thomas, Charles F., Mullon, John J., Shen, K. Robert, Cassivi, Stephen D., Marks, Randolph S., Aubry, Marie Christine, Adjei, Alex A., Yang, Ping, Allen, Mark S., Edell, Eric S., Wigle, Dennis, and Mansfield, Aaron S.

Published
2017
Full Text
View/download PDF

11. RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs

Author

Yeo, Jiyoun, Morales, Diego A., Chen, Tian, Crawford, Erin L., Zhang, Xiaolu, Blomquist, Thomas M., Levin, Albert M., Massion, Pierre P., Arenberg, Douglas A., Midthun, David E., Mazzone, Peter J., Nathan, Steven D., Wainz, Ronald J., Nana-Sinkam, Patrick, Willey, Paige F. S., Arend, Taylor J., Padda, Karanbir, Qiu, Shuhao, Federov, Alexei, Hernandez, Dawn-Alita R., Hammersley, Jeffrey R., Yoon, Youngsook, Safi, Fadi, Khuder, Sadik A., and Willey, James C.

Published
2018
Full Text
View/download PDF

16. An Official American Thoracic Society/American College of Chest Physicians Policy Statement: Implementation of Low-Dose Computed Tomography Lung Cancer Screening Programs in Clinical Practice

Author

Wiener, Renda Soylemez, Gould, Michael K., Arenberg, Douglas A., Au, David H., Fennig, Kathleen, Lamb, Carla R., Mazzone, Peter J., Midthun, David E., Napoli, Maryann, Ost, David E., Powell, Charles A., Rivera, Patricia M., Slatore, Christopher G., Tanner, Nichole T., Vachani, Anil, Wisnivesky, Juan P., and Yoon, Sue H.

Published
2015
Full Text
View/download PDF

21. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.

Author

Tang, Jinyi, Zeng, Cong, Cox, Thomas M., Li, Chaofan, Son, Young Min, Cheon, In Su, Wu, Yue, Behl, Supriya, Taylor, Justin J., Chakaraborty, Rana, Johnson, Aaron J., Shiavo, Dante N., Utz, James P., Reisenauer, Janani S., Midthun, David E., Mullon, John J., Edell, Eric S., Alameh, Mohamad G., Borish, Larry, and Teague, William G.

Abstract

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S–specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs. Breathing stronger immunity with COVID-19 vaccines: Many intramuscular SARS-CoV-2 mRNA–vaccinated people still experience breakthrough Omicron subvariant infection. Despite the Omicron subvariants' immune evasion, T and B cells induced from the vaccine still provide some protection; thus, it is unclear why so many breakthrough infections occur. Here, Tang et al. looked in the blood and bronchoalveolar lavage (BAL) fluid of unvaccinated, COVID-19 convalescent, and SARS-CoV-2 mRNA–vaccinated people. Immune responses in the PBMCs were comparable between the two groups, but the mRNA vaccine did not induce Omicron BA.1–specific neutralizing antibodies and T cells in the lung. In a mouse model, boosting mRNA-vaccinated mice intranasally improved SARS-CoV-2 immunity in the lung. Thus, an intranasal vaccine boosting strategy will be critical to protect people against emerging variants of concern. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Quality of Life and Symptom Burden among Long-Term Lung Cancer Survivors

Author

Yang, Ping, Cheville, Andrea L., Wampfler, Jason A., Garces, Yolanda I., Jatoi, Aminah, Clark, Matthew M., Cassivi, Stephen D., Midthun, David E., Marks, Randolph S., Aubry, Marie-Christine, Okuno, Scott H., Williams, Brent A., Nichols, Francis C., Trastek, Victor F., Sugimura, Hiroshi, Sarna, Linda, Allen, Mark S., Deschamps, Claude, and Sloan, Jeff A.

Published
2012
Full Text
View/download PDF

35. Characterizing phenotypic abnormalities associated with high-risk individuals developing lung cancer using electronic health records from the All of Us researcher workbench.

Author

Na, Jie, Zong, Nansu, Wang, Chen, Midthun, David E, Luo, Yuan, Yang, Ping, and Jiang, Guoqian

Abstract

Objective: The study sought to test the feasibility of conducting a phenome-wide association study to characterize phenotypic abnormalities associated with individuals at high risk for lung cancer using electronic health records.Materials and Methods: We used the beta release of the All of Us Researcher Workbench with clinical and survey data from a population of 225 000 subjects. We identified 3 cohorts of individuals at high risk to develop lung cancer based on (1) the 2013 U.S. Preventive Services Task Force criteria, (2) the long-term quitters of cigarette smoking criteria, and (3) the younger age of onset criteria. We applied the logistic regression analysis to identify the significant associations between individuals' phenotypes and their risk categories. We validated our findings against a lung cancer cohort from the same population and conducted an expert review to understand whether these associations are known or potentially novel.Results: We found a total of 214 statistically significant associations (P < .05 with a Bonferroni correction and odds ratio > 1.5) enriched in the high-risk individuals from 3 cohorts, and 15 enriched in the low-risk individuals. Forty significant associations enriched in the high-risk individuals and 13 enriched in the low-risk individuals were validated in the cancer cohort. Expert review identified 15 potentially new associations enriched in the high-risk individuals.Conclusions: It is feasible to conduct a phenome-wide association study to characterize phenotypic abnormalities associated in high-risk individuals developing lung cancer using electronic health records. The All of Us Research Workbench is a promising resource for the research studies to evaluate and optimize lung cancer screening criteria. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

36. Idiopathic Nonspecific Interstitial Pneumonia: Report of an American Thoracic Society Project

Author

Travis, William D., Hunninghake, Gary, King, Talmadge E., Jr., Lynch, David A., Colby, Thomas V., Galvin, Jeffrey R., Brown, Kevin K., Chung, Man Pyo, Cordier, Jean-François, du Bois, Roland M., Flaherty, Kevin R., Franks, Teri J., Hansell, David M., Hartman, Thomas E., Kazerooni, Ella A., Kim, Dong Soon, Kitaichi, Masanori, Koyama, Takashi, Martinez, Fernando J., Nagai, Sonoko, Midthun, David E., Müller, Nestor L., Nicholson, Andrew G., Raghu, Ganesh, Selman, Moisés, and Wells, Athol

Published
2008
Full Text
View/download PDF

41. Alpha[sub 1]-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk

Author

Yang, Ping, Sun, Zhifu, Krowka, Michael J., Aubry, Marie-Christine, Bamlet, William R., Wampfler, Jason A., Thibodeau, Stephen N., Katzmann, Jerry A., Allen, Mark S., Midthun, David E., Marks, Randolph S., and de Andrade, Mariza

Subjects
Alpha 1-antitrypsin deficiency -- Complications and side effects, Alpha 1-antitrypsin deficiency -- Research, Lung cancer -- Genetic aspects, Lung cancer -- Risk factors, Lung cancer -- Research, Smoking -- Health aspects, Lung diseases, Obstructive -- Complications and side effects, Health
Published
2008

Catalog

Books, media, physical & digital resources
See catalog results